Each entry below is independently re-derived from raw source data and cross-checked against the literature before publishing. Null results are reported as directly as positive ones.
Does the LHRH/GnRH receptor (GNRHR), the target of an active TNBC nanoparticle-targeting strategy, express differently across TNBC's molecular subtypes? If it does, that would matter for how consistently a receptor-targeted therapy could work across the disease's biological variants.
Result: no statistically significant difference across subtypes, and no relationship to survival in this cohort (TCGA), a real, well-caveated null result.
A gene-agnostic follow-up to Case Study 01: instead of testing one hand-picked gene, 15 candidates were sourced systematically from Open Targets' TNBC-associated target scores, then tested for subtype- and survival-association with Benjamini–Hochberg FDR correction applied across all 15 together, then scored on druggability (ChEMBL) and TNBC-specific literature coverage (PubMed).
The 8 FDR-significant genes were re-tested against METABRIC, a second, independent cohort (320 TNBC patients, nearly 3x the TCGA cohort) profiled on a different expression platform. 7 of 8 replicated on both. RRM2 did not (TCGA-significant, but p = 0.23 in METABRIC) and is reported as a miss, not dropped.
Status: computational only. Nothing here has been validated at the protein level yet, that's the next step, now underway with wet-lab flow cytometry.